Clinical Trials Logo

Filter by:
NCT ID: NCT05412472 Completed - Renal Impairment Clinical Trials

Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419

Start date: April 4, 2019
Phase: Phase 1
Study type: Interventional

The study is a two-center, Phase 1, open-label, single-dose, one-period, four groups, PK study in subjects with various severities of renal impairment and matched healthy controls.

NCT ID: NCT05412134 Completed - Pediatric Obesity Clinical Trials

Inspiratory Muscle Rehabilitation in Children With Obesity

BREATHE Fit
Start date: August 23, 2022
Phase: N/A
Study type: Interventional

This is a single-center, randomized, SHAM-controlled, parallel assignment, double-masked, interventional trial among children aged 8-17 years (not yet 18 years old) of age with obesity (n=30), recruited from the Duke Healthy Lifestyles Clinic to test the effectiveness of inspiratory muscle rehabilitation (IMR) as an acceptable add-on intervention to reduce dyspnea (feeling short-of-breath or breathless) and to promote greater activity in children with obesity

NCT ID: NCT05412121 Completed - Clinical trials for Rheumatoid Arthritis

Acupressure in Rheumatoid Arthritis

Start date: September 15, 2022
Phase: N/A
Study type: Interventional

The goal of this pilot trial is to better understand if acupressure is feasible and tolerable to people with rheumatoid arthritis.

NCT ID: NCT05412004 Completed - Obesity Clinical Trials

Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

SURMOUNT-OSA
Start date: June 21, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with obstructive sleep apnea and obesity who are both unwilling or unable to use Positive Airway Pressure (PAP) therapy in GPI1 and those who are and plan to stay on PAP therapy in GPI2.

NCT ID: NCT05411939 Completed - Clinical trials for Osteoarthritis, Knee

Investigating the Impact of a Shared Decision-Making Tool

Start date: April 15, 2023
Phase: N/A
Study type: Interventional

The purpose of this research study is to learn more about how the use of a Shared Decision-Making Tool (SDMT) will impact a patient's decision-making to pursue treatment for knee osteoarthritis.

NCT ID: NCT05411861 Completed - Clinical trials for Hallux Valgus and Bunion

Post-Operative Pain and Opioid Reduction Trial After Bunionectomy

MERIT-2
Start date: June 14, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase 2b, randomized, double blind, placebo and active controlled study with an Ascending Dose Stage and an optional Dose Expansion Stage in subjects undergoing bunionectomy.

NCT ID: NCT05411835 Completed - Clinical trials for Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency

Oral Ketones and Exercise Among Patients With Long-chain Fatty Acid Oxidation Disorders

Start date: August 1, 2022
Phase: Early Phase 1
Study type: Interventional

The purpose of the study is to determine if an oral ketone beverage is safe and well-tolerated during moderate intensity exercise in participants with long-chain fatty acid oxidation disorders and if it will raise blood ketones to levels similar to that reported among normal healthy subjects.

NCT ID: NCT05411796 Completed - Menstruation Clinical Trials

In-use Cross-over Study of Two Different Menstrual Cups

Start date: August 7, 2018
Phase: N/A
Study type: Interventional

This study evaluated the safety and tolerability of two different menstrual cups on vaginal health

NCT ID: NCT05411588 Completed - Healthy Volunteers Clinical Trials

A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People

Start date: June 9, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) in healthy participants. This study is seeking participants who: - Are healthy as determined by medical evaluation. - Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. - Have a body mass index (BMI) of 17.5 to 32 kilogram per meter square - a total body weight of more than 50 kilograms (110 pounds) Participants will be divided randomly into 8 different groups. All participants will receive either one PF-07275315 or a harmless treatment that has no medical effect (placebo) intravenous (IV) infusion (given directly into a vein). Participants will take part in this study for up to 541 days. During this time, eligible participants will receive single increasing amounts of PF-07275315 or placebo. Increase will only occur if the sponsor agrees that the next dose is likely to have acceptable safety and tolerability. The follow-up visit will take place 271 days after first treatment.

NCT ID: NCT05411367 Completed - Dry Eye Disease Clinical Trials

A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye

SIDE
Start date: July 28, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of SI-614 ophthalmic solution compared with placebo in patients with dry eye